Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Clinical Trial Budget Preparation and Approvals – V 2.0

Posted on By

BA-BE Studies: SOP for Clinical Trial Budget Preparation and Approvals – V 2.0

Standard Operating Procedure for Clinical Trial Budget Preparation and Approvals in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/038/2025
Supersedes SOP/BA-BE/038/2022
Page No. Page 1 of 13
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for preparing and obtaining approval for the clinical trial budget associated with Bioavailability/Bioequivalence (BA/BE) studies, including cost estimation, review, negotiation, finalization, and documentation.

2. Scope

This SOP applies to all BA/BE studies conducted or sponsored by the organization and covers budgeting activities for internal resources, site payments, CRO services, laboratory testing, volunteer reimbursements, and contingency funds.

3. Responsibilities

  • Clinical Project Manager: Initiates and prepares the draft study budget in consultation with relevant departments.
  • Finance Department: Verifies financial projections, vendor rates, and payment timelines.
  • Regulatory Affairs: Confirms budget covers all submission and approval fees.
  • Site Management Team: Coordinates site budget negotiation and obtains approval from the Principal Investigator.
See also  BA-BE Studies: SOP for Developing Informed Consent Documents - V 2.0

4. Accountability

The Head of Clinical Operations is accountable for ensuring that each BA/BE study has a finalized and approved budget in place before the initiation of any contractual commitments or clinical activities.

5. Procedure

5.1 Budget Planning Initiation

  1. Initiate budget planning during protocol development or feasibility stage.
  2. Use Annexure-1: Clinical Trial Budget Template to list all anticipated line items.

5.2 Cost Components to be Included

  1. Include the following cost elements:
    • Site fees (screening, randomization, completion)
    • Volunteer compensation and meals
    • Clinical supplies and lab kits
    • Bioanalytical sample analysis
    • Regulatory and EC submission fees
    • Insurance premiums
    • CRO/vendor fees
    • Monitoring travel and overheads
    • Archival and TMF maintenance
    • Contingency (5–10%)

5.3 Internal Review and Revisions

  1. Circulate draft budget internally for review using Annexure-2: Budget Review Log.
  2. Revise based on feedback from functional teams.
See also  BA-BE Studies: SOP for Review of SmPC for EU BA/BE Submissions - V 2.0

5.4 Site and Vendor Budget Negotiation

  1. Share budget breakdown with site and CRO for review.
  2. Negotiate line items where required and document changes in Annexure-3: Negotiation Summary Sheet.

5.5 Final Approval and Execution

  1. Compile finalized budget with signatures using Annexure-4: Final Budget Approval Form.
  2. Store all budget documents in the Trial Master File (TMF).
  3. Use approved budget as baseline for future cost tracking and reconciliation.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CRO: Contract Research Organization
  • EC: Ethics Committee
  • TMF: Trial Master File

7. Documents

  1. Clinical Trial Budget Template – Annexure-1
  2. Budget Review Log – Annexure-2
  3. Negotiation Summary Sheet – Annexure-3
  4. Final Budget Approval Form – Annexure-4

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules
  • Internal Clinical Study Finance SOP
See also  BA-BE Studies: SOP for Preparation of Dossiers for US FDA ANDA Submissions - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Clinical Trial Budget Template

Cost Component Estimated Amount (INR) Remarks
Volunteer Compensation ₹2,00,000 Includes meals & travel
Site Management Fees ₹3,00,000 Per subject cost

Annexure-2: Budget Review Log

Reviewer Department Date Comments Status
Sunita Reddy QA 12/04/2025 Add contingency reserve Incorporated

Annexure-3: Negotiation Summary Sheet

Item Original Quote Final Agreed Justification
Bioanalytical Testing ₹4,50,000 ₹4,00,000 Volume-based discount

Annexure-4: Final Budget Approval Form

Study Code Total Budget Approved By Date Signature
BE-043 ₹12,80,000 Dr. Arvind Shah 17/04/2025

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial SOP New budget control process QA Head
17/04/2025 2.0 Added annexures and CRO cost tracking Financial compliance QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Tablets: SOP for Reviewing Blending and Granulation Records – V 2.0
Next Post: API Manufacturing: SOP for Handling Expired Raw Materials – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version